Investigating and Comparing the Association of Fatty Liver with Tamoxifen and Letrozole in Premenopausal Patients with Breast Cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221126056616N1

Enrollment

Registered

2022-12-08

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Breast Cancer. Condition 2: Fatty Liver. Malignant neoplasm of breast Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Patients with Brest cancer treated with Letrozole. Intervention 2: Control group: Patients with Brest cancer treated with Tamoxifen.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Premenopausal breast cancer patients (Progesterone receptor or Estrogen receptor positive).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of fatty liver. Timepoint: 6 months after taking tamoxifen and letrozole drugs. Method of measurement: Ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Nazarinia

Qazvin University of Medical Sciences

m.nazarinia99@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026